John M. Kirkwood

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

John M. Kirkwood
Jan 18, 2025, 14:50 | Blog
Don’t miss the 11th World Congress of Melanoma and 21st EADO Congress
Marco Donia shared a post by Melanoma World Society, on LinkedIn: "Neoadjuvant or Perioperative Immunotherapy:…
Sep 3, 2024, 12:16 | Blog
Pawel Kalinski: The use of TAAs as ubiquitous targets for adoptive T cell therapies in solid tumors
Pawel Kalinski, Senior Vice President for Team Science at Roswell Park Comprehensive Cancer Center, shared on…
Aug 30, 2024, 10:39 | Insight
Article of the day, August 30th, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Aug 28, 2024, 13:52 | Insight
Article of the day, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Aug 9, 2024, 12:57 | Insight
Tony Cillo: Excited to share our paper on anti-PD1+anti-LAG3 therapy in melanoma
Tony Cillo, Assistant professor in the Department of Immunology at the University of Pittsburgh. "Excited…
Jun 25, 2024, 14:38 | Insight
New Paper Alert! Long-Term Benefits of Dabrafenib-Trametinib in Stage III Melanoma: 8-Year COMBI-AD Trial Results
Long-Term Benefits of Dabrafenib-Trametinib in Stage III Melanoma: 8-Year COMBI-AD Trial Results       …
Apr 2, 2024, 12:20 | Insight
Ankit Mangla: Our analysis of data from neoadjuvant IO trials in melanoma has been published in JAMA Oncology
Ankit Mangla, Sarcoma and Cutaneous Oncology Specialist at the Seidman Cancer Center, shared a post…
All: 7 Posts: 1 - 100
Special Coverage